Stemnovate’s compliant organs-on-chip platforms integrate stem cell research and tissue engineering to provide physiological alternative to cancer lines and animal models for precision drug discovery and screening.
Stemnovate is soon introducing the microfluidic platform for DNA synthesis
|Therapautics Area||Multi Therapautics|
|Investment Portfolio||Pre-Fund Investment|
|Co-Investors||Business Angels, Innovate UK|